Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Design Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026.
- Filed
- Apr 28, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-187063
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | $(17,636) | $(17,715) |
| Reconciliation of net loss to net cash used in operating activities: | ||
| Depreciation | 157 | 159 |
| Stock-based compensation | 3,924 | 3,539 |
| Amortization of premiums on investment securities, net | (147) | (1,060) |
| Non-cash lease expense | 69 | (4) |
| Change in operating assets and liabilities: |
Item 1. Financial Statements.
FAQ
- What is Design Therapeutics, Inc.'s D&A?
- Design Therapeutics, Inc. (DSGN) reported D&A of $157K in Q1 2026.
- How has Design Therapeutics, Inc.'s D&A changed year-over-year?
- Design Therapeutics, Inc.'s D&A decreased by 1.3% year-over-year, from $159K to $157K.
- What is the long-term trend for Design Therapeutics, Inc.'s D&A?
- Over 4 years (2021 to 2025), Design Therapeutics, Inc.'s D&A has grown at a 48.2% compound annual growth rate (CAGR), from $129K to $622K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Design Therapeutics, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude